The JAK2 V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders Leukemia (2008) The discovery of the JAK2 V617F somatic mutation was a tremendous breakthrough for the understanding of the physiopathology of the myeloproliferative disorders (MPD) and contributed to define more accurately these diseases. 1 However, there is no information on the time of appearance of this acquired event and the period needed for the development of the disease, the presence of the mutation being usually tested for a suspected MPD. Figure 3 Percentage (%) of apoptosis of Aliargentumycine (AAgM) on HL-60 (dotted bars) and Jurkat (diagonal bars) analyzed by flow cytometry. Cells were treated for 48 h with AAgM. Following treatment, apoptotic cells were measured by flow cytometric analyses. Cells were seeded at 1 Â 10 5 cells/ml and were treated with Aliargentumycine to induce apoptosis at 0.03, 4 and 60 mM for Phases I, II and III, respectively. Positive and negative controls were employed by incubating HL-60 cells at 451C for 45 min (Positive) and by maintaining the cells in media without any cytotoxic drugs (Control), respectively. Detection of apoptosis was done by the DeadEnd Colorimetric TUNEL assay for the detection of apoptosis in cultured cells as described in Promega kit.
Letters to the Editor
The study of 72 families with MPD gave us the opportunity to analyze the presence of the JAK2 V617F mutation in relatives considered unaffected at inclusion into the study owing to their normal cell blood counts and the absence of MPD clinical signs or symptoms. 2 Among 238 healthy relatives, we found the JAK2 V617F mutation in three (two males and one female) of them with an allele burden ranging from 5 to 14% using a sequencing approach. In two of them, endogenous erythroid colonies (EECs) were present and were positive for the JAK2 V617F mutation. The analysis of individual EECs collected at inclusion showed a mix of homozygous and heterozygous colonies in both cases. Hematological characteristics at inclusion and follow-up are shown in the Table 1 . The increase of JAK2 V617F allele burden mutation was associated with the development of a polycythemia vera (PV) and an essential thrombocythemia (ET) in the two former cases. By contrast, no change in level of the JAK2 V617F expression was observed in the third case which remains asymptomatic after a follow-up of 6 years. Elsewhere, after a median follow-up of 7 (3.7-10.1) years, no novel case of MPD has been revealed in our cohort, among the other relatives negative for the JAK2 V617F mutation at inclusion. Interestingly, several groups have recently analyzed the presence of the JAK2 V617F mutation in healthy individuals. Surprisingly, Sidon et al. 3 and Xu et al. 6 have reported the presence of the JAK2 V617F mutation in approximately 10% of healthy donors (5/52 and 37/3935, respectively), whereas no mutation was found in two others studies. [3] [4] [5] [6] Moreover, the mutation has not been detected in the DNA controls analyzed by the different groups, which initially identified the JAK2 V617F mutation in MPD. Although differences in the sensitivity due to the method used in these studies may explain these discrepancies, it is noteworthy that an observed frequency of 10% in healthy individuals is not in accordance with the annual incidence of sporadic MPD which is very low, nearly five new cases per 100 000 per year taken together PV and ET. Only longterm follow-up of these healthy individuals positive for the JAK2 mutation will allow concluding on the significance of this low level of JAK2 V617F mutation detection. Very similar results for Bcr-Abl were reported in healthy individuals 10 years ago with no confirmation till now of the occurrence of overt CML. 7, 8 Conversely in the setting of familial cases, the presence of a genetic factor of predisposition may better explain our results showing that JAK2 V617F mutation precedes the development of MPD. Overt MPD needs several years to occur, suggesting that other acquired events that may depend on patient age and type of MPD have to occur to allow the proliferation of the abnormal clone. Finally, this observation raises the question of systemic JAK2 V617F genetic testing in families with at least two cases of MPD.
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